首页> 外文OA文献 >Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis

【2h】

Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis

机译：PF-06438179 / GP1111（一种英雄纤维生素生物酸）的人口药代动力学和中度患者的参考英夫利昔单抗，以严重活性类风湿性关节炎

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Rameshraja Palaparthy; Muhammad I. Rehman; Oliver von Richter; Donghua Yin;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis [J] . Rameshraja Palaparthy, Muhammad I. Rehman, Oliver von Richter, Expert opinion on biological therapy . 2019,第7a12期

机译：PF-06438179 / GP1111（一种英雄纤维生素生物酸）的人口药代动力学和中度患者的参考英夫利昔单抗，以严重活跃的类风湿性关节炎
2. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial [J] . BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2020,第2期

机译：长期疗效，安全性和免疫原性的incriximab（IFX）生物仿制性，PF-06438179 / GP1111，用于从参考IFX或持续生物综合治疗切换后的类风湿性关节炎患者：一周54-78来自随机，双盲的数据，III期试验
3. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study [J] . Smolen Josef S., Choe Jung-Yoon, Prodanovic Nenad, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第2期

机译：与类风湿性关节炎患者的持续参考英夫利昔单抗和SB2切换到生物蛋白酶和SB2后的安全性，免疫原性和功效与类风湿性关节炎患者的持续参考inciximab和SB2相比：随机，双盲，III期转型研究的结果
4. Human Antichimeric Antibodies to Infliximab and Infusion-Related Allergic Reactions in Patients with Rheumatoid Arthritis [C] . D. Wouters, S. Stapel, M. Vis, Collegium Internationale Allergologicum . 2007

机译：人的苯甲酸纤维化率和类风湿性关节炎患者的infumency相关过敏反应的抗体抗体
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy [O] . Stanley B. Cohen, Rieke Alten, Hideto Kameda, 2018

机译：随机对照试验比较了PF-06438179 / GP1111（英夫利昔单抗生物仿制药）和英夫利昔单抗参考产品治疗甲氨蝶呤治疗中度至重度活动性类风湿关节炎
7. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy [O] . Stanley B. Cohen, Rieke Alten, Hideto Kameda, 2018

机译：随机对照试验比较PF-06438179 / GP1111（英夫利昔单抗生物酸）和英夫利昔单抗参考产物，用于治疗中度至严重活性类风湿性关节炎，尽管甲氨蝶呤治疗

Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis

著录项

引文网络

相似文献

相关主题

期刊订阅